{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:38:56Z","timestamp":1792571936188,"version":"4.5.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Robust transient knockdown strategies are critical to oligonucleotide therapeutic development, yet ineffective and variable RNA delivery across experimental models continues to limit target validation. Efficient delivery of nucleic acids into acute myeloid leukemia (AML) cells is particularly challenging due to their immature, suspension phenotype. Here, we performed a head-to-head benchmarking comparison of commonly used chemical transfection reagents (Lipofectamine 3000, Lipofectamine 2000, RNAiMAX, INTERFERin) alongside a physical electroporation approach (Lonza nucleofection) across four genetically distinct AML cell lines (THP-1, OCI-AML3, MV4-11, MOLM-14). To establish recommended RNA delivery strategies, we used small-interfering RNA (siRNA) and quantified functional knockdown by RT-qPCR, with protein-level validation and paired assessment of post-transfection viability. Lipid-based formulations were most effective in more differentiated AML cell lines (for example, THP-1 and OCI-AML3), whereas more immature lines (MV4-11 and MOLM-14) were poorly responsive to chemical transfection but efficiently transfected by electroporation. A short serum-free incubation period enhanced lipid-mediated delivery in permissive lines and produced measurable gains in more resistant models. Transfection-associated cytotoxicity was strongly method-dependent, with lipid-based reagents producing minimal to modest viability losses and nucleofection causing substantially greater short-term reductions in viable cell numbers. Based on this systematic comparison, most chemical reagents supported efficient delivery in THP-1 and, to a lesser extent, OCI-AML3, while MV4-11 and MOLM-14 demonstrated strict dependence on electroporation for meaningful intracellular uptake. Together, our results define a concise, qPCR-guided workflow, validated at the protein level, that provides a replicable, decision-oriented framework for selecting efficient and fit-for-purpose short RNA delivery strategies in AML cell lines.<\/jats:p>","DOI":"10.1093\/biomethods\/bpag014","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:25:00Z","timestamp":1771849500000},"source":"Crossref","is-referenced-by-count":0,"title":["One size does not fit all: A comparative framework for optimizing ribonucleic acid transfection across acute myeloid leukemia cell lines"],"prefix":"10.1093","volume":"11","author":[{"given":"Monika M","family":"Kojic","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, McGill University , Montreal, QC, H3G 1Y6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, McGill University , Montreal, QC, H3G 1Y6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Kovecses","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, McGill University , Montreal, QC, H3G 1Y6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3750-6027","authenticated-orcid":false,"given":"Maureen","family":"McKeague","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, McGill University , Montreal, QC, H3G 1Y6,","place":["Canada"]},{"name":"Department of Chemistry, McGill University , Montreal, QC, H3A 0B8,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2026102103474134200_bpag014-B1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3727\/096504020X15965357399750","article-title":"Outcomes of patients with acute myeloid leukemia who relapse after 5 years of complete remission","volume":"28","author":"Patel","year":"2021","journal-title":"Oncol Res"},{"key":"2026102103474134200_bpag014-B2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.beha.2013.10.005","article-title":"Relapsed acute myeloid leukemia: why is there no standard of care?","volume":"26","author":"Ravandi","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"2026102103474134200_bpag014-B3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"2026102103474134200_bpag014-B4","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"2026102103474134200_bpag014-B5","doi-asserted-by":"crossref","first-page":"e2010651","DOI":"10.1001\/jamanetworkopen.2020.10651","article-title":"Association of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials","volume":"3","author":"Unger","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026102103474134200_bpag014-B6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3324\/haematol.2022.280847","article-title":"COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association Survey (EPICOVIDEHA)","volume":"108","author":"Marchesi","year":"2023","journal-title":"Haematologica"},{"key":"2026102103474134200_bpag014-B7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gde.2016.03.011","article-title":"Genetic and epigenetic heterogeneity in acute myeloid leukemia","volume":"36","author":"Li","year":"2016","journal-title":"Curr Opin Genet Dev"},{"key":"2026102103474134200_bpag014-B8","doi-asserted-by":"crossref","first-page":"e2211429119","DOI":"10.1073\/pnas.2211429119","article-title":"Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia","volume":"119","author":"Cheng","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026102103474134200_bpag014-B9","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1038\/sj.onc.1209638","article-title":"siRNA-mediated AML1\/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8; 21)-positive cell lines and primary AML blasts","volume":"25","author":"Dunne","year":"2006","journal-title":"Oncogene"},{"key":"2026102103474134200_bpag014-B10","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s41409-020-0966-6","article-title":"PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity","volume":"55","author":"van Ens","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2026102103474134200_bpag014-B11","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1177\/147323001103900508","article-title":"Effect of small interfering RNA targeting wild-type FLT3 in acute myeloid leukaemia cells in vitro and in vivo","volume":"39","author":"Wang","year":"2011","journal-title":"J Int Med Res"},{"key":"2026102103474134200_bpag014-B12","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.7314\/APJCP.2013.14.12.7719","article-title":"siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells","volume":"14","author":"Karami","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026102103474134200_bpag014-B13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J Pathol"},{"key":"2026102103474134200_bpag014-B14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat Mater"},{"key":"2026102103474134200_bpag014-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","article-title":"Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics","volume":"203","author":"Lorenzer","year":"2015","journal-title":"J Control Release"},{"key":"2026102103474134200_bpag014-B16","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/17425247.2023.2251890","article-title":"siRNA therapeutics: insights, challenges, remedies and future prospects","volume":"20","author":"Khan","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"key":"2026102103474134200_bpag014-B17","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood.V110.11.1604.1604","article-title":"Activity and mechanism of action of AS1411 in acute myeloid leukemia cells","volume":"110","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"2026102103474134200_bpag014-B18","doi-asserted-by":"crossref","first-page":"102643","DOI":"10.1016\/j.omtn.2025.102643","article-title":"RNA activation of CEBPA improves leukemia treatment","volume":"36","author":"Kovecses","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026102103474134200_bpag014-B19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2026102103474134200_bpag014-B20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2026102103474134200_bpag014-B21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/cells10030591","article-title":"Small activating RNAs: towards the development of new therapeutic agents and clinical treatments","volume":"10","author":"Ghanbarian","year":"2021","journal-title":"Cells"},{"key":"2026102103474134200_bpag014-B22","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","article-title":"MTL-CEBPA, a small activating RNA therapeutic upregulating C\/EBP-\u03b1, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial","volume":"26","author":"Sarker","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026102103474134200_bpag014-B23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2018.07.003","article-title":"Aptamers: uptake mechanisms and intracellular applications","volume":"134","author":"Yoon","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"2026102103474134200_bpag014-B24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4155\/tde-2018-0061","article-title":"Developing small activating RNA as a therapeutic: current challenges and promises","volume":"10","author":"Kwok","year":"2019","journal-title":"Ther Deliv"},{"key":"2026102103474134200_bpag014-B25","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1093\/nar\/gkaa576","article-title":"A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics","volume":"48","author":"Deprey","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026102103474134200_bpag014-B26","doi-asserted-by":"crossref","first-page":"e11165","DOI":"10.7717\/peerj.11165","article-title":"Transfection types, methods and strategies: a technical review","volume":"9","author":"Chong","year":"2021","journal-title":"PeerJ"},{"key":"2026102103474134200_bpag014-B27","doi-asserted-by":"crossref","first-page":"9739","DOI":"10.1073\/pnas.1409431111","article-title":"Probing the inherent stability of siRNA immobilized on nanoparticle constructs","volume":"111","author":"Barnaby","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026102103474134200_bpag014-B28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: how do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA"},{"key":"2026102103474134200_bpag014-B29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"key":"2026102103474134200_bpag014-B30","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3390\/pharmaceutics14112520","article-title":"siRNA functionalized lipid nanoparticles (LNPs) in management of diseases","volume":"14","author":"Kalita","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026102103474134200_bpag014-B31","first-page":"100283","article-title":"Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery","volume":"8","author":"Haque","year":"2024","journal-title":"Int J Pharm X"},{"key":"2026102103474134200_bpag014-B32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"2026102103474134200_bpag014-B33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/mt.2013.210","article-title":"Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability","volume":"22","author":"He","year":"2014","journal-title":"Mol Ther"},{"key":"2026102103474134200_bpag014-B34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/bbrc.1998.9744","article-title":"Expression of caveolin-1 in human T cell leukemia cell lines","volume":"253","author":"Hatanaka","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"2026102103474134200_bpag014-B35","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3390\/biomedicines10112687","article-title":"Systemic optimization of gene electrotransfer protocol using hard-to-transfect UT-7 cell line as a model","volume":"10","author":"Vadeikiene","year":"2022","journal-title":"Biomedicines"},{"key":"2026102103474134200_bpag014-B36","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.exphem.2011.08.003","article-title":"Nonviral transfection of leukemic primary cells and cells lines by siRNA-a direct comparison between nucleofection and accell delivery","volume":"39","author":"Larsen","year":"2011","journal-title":"Exp Hematol"},{"key":"2026102103474134200_bpag014-B37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-4939-6337-9_7","article-title":"RNAi screening of leukemia cells using electroporation","volume":"1470","author":"Agarwal","year":"2016","journal-title":"Methods Mol Biol"},{"key":"2026102103474134200_bpag014-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-0556-2-1","article-title":"Novel non-viral method for transfection of primary leukemia cells and cell lines","volume":"2","author":"Schakowski","year":"2004","journal-title":"Genet Vaccines Ther"},{"key":"2026102103474134200_bpag014-B39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/mt.2016.6","article-title":"Induced apoptosis investigation in wild-type and FLT3-ITD acute myeloid leukemia cells by nanochannel electroporation and single-cell qRT-PCR","volume":"24","author":"Gao","year":"2016","journal-title":"Mol Ther"},{"key":"2026102103474134200_bpag014-B40","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/s41598-020-59790-x","article-title":"The effects of electroporation buffer composition on cell viability and electro-transfection efficiency","volume":"10","author":"Sherba","year":"2020","journal-title":"Sci Rep"},{"key":"2026102103474134200_bpag014-B41","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s10439-012-0678-1","article-title":"Physical non-viral gene delivery methods for tissue engineering","volume":"41","author":"Mellott","year":"2013","journal-title":"Ann Biomed Eng"},{"key":"2026102103474134200_bpag014-B42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature19764","article-title":"In vitro and ex vivo strategies for intracellular delivery","volume":"538","author":"Stewart","year":"2016","journal-title":"Nature"},{"key":"2026102103474134200_bpag014-B43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12033-010-9302-5","article-title":"Comparison of transfection efficiency of nonviral gene transfer reagents","volume":"46","author":"Yamano","year":"2010","journal-title":"Mol Biotechnol"},{"key":"2026102103474134200_bpag014-B44","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/btpr.472","article-title":"Serum starvation improves transient transfection efficiency in differentiating embryonic stem cells","volume":"26","author":"Wallenstein","year":"2010","journal-title":"Biotechnol Prog"},{"key":"2026102103474134200_bpag014-B45","doi-asserted-by":"crossref","first-page":"V","DOI":"10.1038\/nmeth919","article-title":"Optimizing knockdown of gene expression using the TriFECTa\u2122 dicer-substrate RNAi reagent system","volume":"3","author":"Rose","year":"2006","journal-title":"Nat Methods"},{"key":"2026102103474134200_bpag014-B46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/cr.2016.22","article-title":"saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription","volume":"26","author":"Portnoy","year":"2016","journal-title":"Cell Res"},{"key":"2026102103474134200_bpag014-B47","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/acscentsci.9b00174","article-title":"Uptake and fate of fluorescently labeled DNA nanostructures in cellular environments: a cautionary tale","volume":"5","author":"Lacroix","year":"2019","journal-title":"ACS Cent Sci"},{"key":"2026102103474134200_bpag014-B48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41586-022-05040-1","article-title":"Structures of the human CST-Polalpha-primase complex bound to telomere templates","volume":"608","author":"He","year":"2022","journal-title":"Nature"},{"key":"2026102103474134200_bpag014-B49","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/acsptsci.0c00120","article-title":"RNA targeting in acute myeloid leukemia","volume":"3","author":"Messikommer","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2026102103474134200_bpag014-B50","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.3390\/ijms21124245","article-title":"Involvement of POLA2 in double strand break repair and genotoxic stress","volume":"21","author":"Dang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026102103474134200_bpag014-B51","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12935-023-02949-z","article-title":"Overexpression of POLA2 in hepatocellular carcinoma is involved in immune infiltration and predicts a poor prognosis","volume":"23","author":"Liu","year":"2023","journal-title":"Cancer Cell Int"},{"key":"2026102103474134200_bpag014-B52","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.3390\/cancers12092613","article-title":"DNA polymerase alpha subunit B is a binding protein for erlotinib resistance in non-small cell lung cancer","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026102103474134200_bpag014-B53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/cas.13170","article-title":"MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells","volume":"108","author":"Nishioka","year":"2017","journal-title":"Cancer Sci"},{"key":"2026102103474134200_bpag014-B54","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/s41375-024-02321-8","article-title":"Pivotal role of the endoplasmic reticulum stress-related XBP1s\/miR-22\/SIRT1 axis in acute myeloid leukemia apoptosis and response to chemotherapy","volume":"38","author":"Philippe","year":"2024","journal-title":"Leukemia"},{"key":"2026102103474134200_bpag014-B55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nature07710","article-title":"AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA","volume":"458","author":"Fernandes-Alnemri","year":"2009","journal-title":"Nature"},{"key":"2026102103474134200_bpag014-B56","doi-asserted-by":"crossref","first-page":"37849","DOI":"10.1038\/srep37849","article-title":"Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines","volume":"6","author":"Nakamura","year":"2016","journal-title":"Sci Rep"},{"key":"2026102103474134200_bpag014-B57","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s43018-022-00331-y","article-title":"Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress","volume":"3","author":"Bonagas","year":"2022","journal-title":"Nat Cancer"},{"key":"2026102103474134200_bpag014-B58","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1182\/blood-2010-03-272591","article-title":"Cells expressing FLT3\/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy","volume":"116","author":"Fan","year":"2010","journal-title":"Blood"},{"key":"2026102103474134200_bpag014-B59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.leukres.2017.05.004","article-title":"Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia","volume":"58","author":"Gopalakrishnapillai","year":"2017","journal-title":"Leuk Res"},{"key":"2026102103474134200_bpag014-B60","doi-asserted-by":"crossref","first-page":"15752","DOI":"10.1038\/s41598-018-33982-y","article-title":"Repression of Mcl-1 expression by the CDC7\/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML","volume":"8","author":"O\u2019 Reilly","year":"2018","journal-title":"Sci Rep"},{"key":"2026102103474134200_bpag014-B61","doi-asserted-by":"crossref","first-page":"101512","DOI":"10.1016\/j.xpro.2022.101512","article-title":"RNA interference protocol to silence oncogenic drivers in leukemia cell lines","volume":"3","author":"Beyer","year":"2022","journal-title":"STAR Protoc"},{"key":"2026102103474134200_bpag014-B62","doi-asserted-by":"crossref","first-page":"107871","DOI":"10.1016\/j.bioelechem.2021.107871","article-title":"Cell death due to electroporation \u2013 a review","volume":"141","author":"Batista Napotnik","year":"2021","journal-title":"Bioelectrochemistry"},{"key":"2026102103474134200_bpag014-B63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10439-023-03309-8","article-title":"Dynamics of cell death due to electroporation using different pulse parameters as revealed by different viability assays","volume":"52","author":"Peng","year":"2024","journal-title":"Ann Biomed Eng"},{"key":"2026102103474134200_bpag014-B64","doi-asserted-by":"crossref","first-page":"7718","DOI":"10.1002\/jcp.27890","article-title":"Serum-reduced media impacts on cell viability and protein expression in human lung epithelial cells","volume":"234","author":"Rashid","year":"2019","journal-title":"J Cell Physiol"},{"key":"2026102103474134200_bpag014-B65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0005-2736(01)00448-5","article-title":"Interference of serum with lipoplex-cell interaction: modulation of intracellular processing","volume":"1560","author":"Zuhorn","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"2026102103474134200_bpag014-B66","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layzer","year":"2004","journal-title":"RNA"},{"key":"2026102103474134200_bpag014-B67","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1021\/la200450x","article-title":"Influence of biological media on the structure and behavior of ferrocene-containing cationic lipid\/DNA complexes used for DNA delivery","volume":"27","author":"Golan","year":"2011","journal-title":"Langmuir"},{"key":"2026102103474134200_bpag014-B68","doi-asserted-by":"crossref","first-page":"10010","DOI":"10.1093\/nar\/gkz805","article-title":"Signatures of cell death and proliferation in perturbation transcriptomics data\u2014from confounding factor to effective prediction","volume":"47","author":"Szalai","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026102103474134200_bpag014-B69","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1182\/bloodadvances.2020002666","article-title":"Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis","volume":"5","author":"Dykstra","year":"2021","journal-title":"Blood Adv"},{"key":"2026102103474134200_bpag014-B70","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41375-025-02791-4","article-title":"CRISPR\/Cas9-mediated t(4; 11) translocation in human hematopoietic stem\/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage","volume":"40","author":"Benz","year":"2026","journal-title":"Leukemia"},{"key":"2026102103474134200_bpag014-B71","doi-asserted-by":"crossref","first-page":"12764","DOI":"10.18632\/oncotarget.14463","article-title":"The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"2026102103474134200_bpag014-B72","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1158\/2159-8290.CD-18-1040","article-title":"Mutant and wild-type isocitrate dehydrogenase 1 share enhancing mechanisms involving distinct tyrosine kinase cascades in cancer","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"key":"2026102103474134200_bpag014-B73","first-page":"1153","article-title":"MicroRNA-205 downregulates mixed-lineage-AF4 oncogene expression in acute lymphoblastic leukemia","volume":"6","author":"Dou","year":"2013","journal-title":"Onco Targets Ther"},{"key":"2026102103474134200_bpag014-B74","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1039\/C4NR01510J","article-title":"A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia","volume":"6","author":"Yang","year":"2014","journal-title":"Nanoscale"},{"key":"2026102103474134200_bpag014-B75","first-page":"A3.B.1","article-title":"Trypan blue exclusion test of cell viability","volume":"111","author":"Strober","year":"2015","journal-title":"Curr Protoc Immunol"}],"container-title":["Biology Methods and Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biomethods\/advance-article-pdf\/doi\/10.1093\/biomethods\/bpag014\/67093901\/bpag014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomethods\/article-pdf\/11\/1\/bpag014\/67093901\/bpag014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomethods\/article-pdf\/11\/1\/bpag014\/67093901\/bpag014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:47:59Z","timestamp":1792568879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biomethods\/article\/doi\/10.1093\/biomethods\/bpag014\/8496273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/biomethods\/bpag014","relation":{},"ISSN":["2396-8923"],"issn-type":[{"value":"2396-8923","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"bpag014"}}